Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–58 of 58 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Oral L-Arginine Clear all
Active, not recruiting Phase 1 Interventional

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

NCT04603001
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
Interventions
LY3410738, Venetoclax, Azacitidine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Terminated Phase 1 Interventional

Prospective L-arginine Study

NCT01485757
View directory record Official record
Conditions
Heart Transplant
Interventions
L-arginine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
8 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients

NCT01223937
View directory record Official record
Conditions
Nocturia
Interventions
Desmopressin, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
41
States / cities
Huntsville, Alabama • Scottsdale, Arkansas • Foothill Ranch, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Not applicable Interventional Results available

Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

NCT00775684
View directory record Official record
Conditions
Pre-diabetes, Type 2 Diabetes
Interventions
Exenatide, Sitagliptin, Glimepiride
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Assess the Gingivitis and Plaque Effects of Various Dentifrices

NCT06140784
View directory record Official record
Conditions
Gingivitis
Interventions
0.76% Sodium Monofluorophosphate Dentifrice, 0.454% Stannous Fluoride Dentifrice
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Whittier, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Maximal Use Study to Determine the Pharmacokinetics of L-arginine After Exaggerated Oral Use of COL101

NCT06182267
View directory record Official record
Conditions
Caries,Dental
Interventions
L Arginine, Sodium Fluoride
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices in Comparison With 0.24% Sodium Fluoride (1100 Ppm F) Dentifrice Control in 10 to 14-year-old Children

NCT04750902
View directory record Official record
Conditions
Dental Caries
Interventions
0.24% Sodium Fluoride Dentifrice, 1.5% Arginine Dentifrice, 4.0% Arginine Dentifrice, 8.0% Arginine Dentifrice
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
10 Years to 14 Years
Enrollment
2,025 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
8
States / cities
Loma Linda, California • Gainesville, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Estrogen and Microvascular Function

NCT06043310
View directory record Official record
Conditions
Estrogen, Cardiovascular Diseases, Microvasculature, Oral Contraceptive Use
Interventions
Nω-nitro-L-arginine methyl ester (L-NAME), Acetylcholine, Sodium Nitroprusside
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Recruiting Phase 1 Interventional

Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)

NCT06280482
View directory record Official record
Conditions
Smooth Muscle Dysfunction Syndrome (SMDS)
Interventions
Nicotinamide riboside (NR)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 4, 2026, 1:24 PM EDT
Recruiting Phase 1 Interventional

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NCT07277413
View directory record Official record
Conditions
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma
Interventions
IDE892, IDE397
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 4, 2026, 1:24 PM EDT